 |
 |
|
|
RESÚMENES ENERO 2006 |
Psychotic Disorders & Antipsychotics
(Haga un click en la información del journal
para acceder al resúmen)
Magnetic
resonance imaging study of the ventricle–brain ratio in parents of
schizophrenia subjects
Koichi Ohara, Yumi Sato, Shigeru Tanabu, Kimiko Yoshida and Haruo Shibuya
At
therapeutic concentrations, olanzapine does not affect
basal or insulin-stimulated glucose transport in 3T3-L1 adipocytes
Katherine
A. Robinson, Sherif Z. Yacoub
Wasef and Maria G. Buse
Neurological
soft signs and positive treatment response to olanzapine
in chronic schizophrenia
Levent Sevincok
and Beyza Topaloglu
Quetiapine has
equivalent efficacy and superior tolerability to risperidone
in the treatment of schizophrenia with predominantly negative symptoms
M. Riedel, N. Müller, M. Strassnig, I. Spellmann,
R. R. Engel, R. Musil, S. Dehning, A. Douhet,
M. J. Schwarz and H.–J. Mölle
European
Archives of Psychiatry and Clinical Neuroscience 2005;
Volume 255, Number 6: 432 - 437
Effects of cytochrome
P450 3A modulators ketoconazole and carbamazepine on quetiapine
pharmacokinetics
Grimm SW,
Br J Clin Pharmacol.
2006 Jan;61(1):58-69
Adjunct Divalproex or
Lithium to Clozapine in Treatment-Resistant
Schizophrenia
Deanna L. Kelly,
Robert R. Conley, Stephanie Feldman, Yang Yu,
Robert P. McMahon and Charles M. Richardson
Psychiatric
Quarterly 2006; Volume 77, Number 1: 81 - 95
Antipsychotic
drugs cause glial cell line–derived neurotrophic factor secretion from C6 glioma
cells
Zongjun Shao, Lillian E. Dyck, Haitao Wang, Xin-Min Li
J Psychiatry Neurosci 2006;31(1):32-7
Cannabis-induced psychosis and subsequent
schizophrenia-spectrum disorders: follow-up study of 535 incident cases
Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jorgensen P
Br J Psychiatry. 2005 Dec;187:510-5
Reducing the Dose of Antipsychotic Agents
Ameliorates Visual Hypersensitivity Attack: An Ideal Treatment Option in Terms
of the Adverse Effect
Uchida, Hiroyuki; Suzuki, Takefumi;
Yamazawa, Ryoko; Tomita,
Masayuki; Nemoto, Takahiro; Kimura, Yoshie; Watanabe, Koichiro; Imasaka, Yasushi; Kashima, Haruo
Journal of Clinical Psychopharmacology. 26(1):50-55, February 2006
Is Quality of Life Among Minimally Symptomatic
Patients With Schizophrenia Better Following Withdrawal or Continuation of
Antipsychotic Treatment?
Beasley, Charles M. Jr; Sutton,
Virginia K.; Taylor, Cindy C.; Sethuraman, Gopalan; Dossenbach, Martin; Naber, Dieter
Journal of Clinical Psychopharmacology.
26(1):40-44, February 2006
The
gluten connection: the association between schizophrenia and celiac disease
A. E. Kalaydjian, W. Eaton, N. Cascella, A. Fasano
Acta Psychiatrica
Scandinavica.
Volume 113 Page 82 - February 2006
Increased
risk of extrapyramidal side-effect treatment
associated with atypical antipsychotic polytherapy
R. M. Carnahan, B. C. Lund, P. J. Perry, E. A. Chrischilles
Acta Psychiatrica
Scandinavica.
Volume 113 Page 135 - February 2006
An
exploratory open-label trial of aripiprazole as an
adjuvant to clozapine therapy in chronic
schizophrenia
D. C. Henderson, L. Kunkel, D. D. Nguyen, C. P. Borba, T. B. Daley, P. M. Louie, O. Freudenreich,
C. Cather, A. E. Evins, D.
C. Goff
Acta Psychiatrica
Scandinavica.
Volume 113 Page 142 - February 2006
Olanzapine Versus Risperidone in Newly
Admitted Acutely Ill Psychotic Patients
Kraus JE, Sheitman BB, Cook A, Reviere R,
Lieberman JA
J Clin
Psychiatry. 2005 Dec;66(12):1564-1568
Dosing of quetiapine in
schizophrenia: how clinical practice differs from registration studies
Citrome L, Jaffe A, Levine J, Lindenmayer JP
J Clin
Psychiatry. 2005 Dec;66(12):1512-6
Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations
Aichhorn, Wolfgang; Marksteiner, Josef; Walch,
Thomas; Zernig, Gerald; Saria,
Alois; Kemmler, Georg
International Clinical Psychopharmacology. 21(2):81-85, March 2006
Amisulpride
treatment of clozapine-induced hypersalivation
in schizophrenia patients: a randomized, double-blind, placebo-controlled
cross-over study
Kreinin, Anatoly; Novitski, Dmitri; Weizman, Abraham
International Clinical
Psychopharmacology. 21(2):99-103,
March 2006
No
evidence of time trends in the urban–rural differences in schizophrenia risk
among five million people born in
CARSTEN BØCKER PEDERSEN
Psychological
Medicine (2006), 36: 211-219
Sarah I.
Tarbox and Michael F. Pogue-Geile
Schizophrenia Research. Volume 81, Issues 2-3, 31 January 2006, Pages 125-137
Tardive
dyskinesia: Analysis of outpatients with
schizophrenia from Africa and the Middle East, Asia, Central and Eastern
Europe, and
Siegfried
Kasper, Amanda J. Lowry, Andrew Hodge, Istvan Bitter
and Martin Dossenbach
Schizophrenia Research. Volume 81, Issues 2-3, 31 January 2006, Pages 139-143
A. Trandafir, A. Méary, F. Schürhoff, M. Leboyer and A. Szöke
Schizophrenia Research. Volume 81, Issues 2-3, 31 January 2006, Pages 217-226
Schizotypy is increased in mixed-handers, especially
right-handed writers who use the left hand for primary actions
Marian
Annett and Paula Moran
Schizophrenia Research. Volume 81, Issues 2-3, 31 January 2006, Pages 239-246
Antioxidant
enzymes and lipid peroxidation in different forms of
schizophrenia treated with typical and atypical antipsychotics
Xiang Yang Zhang, Yun
Long Tan, Lian Yuan Cao, Gui Ying Wu, Qi Xu, Yan Shen
and Dong Feng Zhou
Schizophrenia Research. Volume 81, Issues 2-3, 31 January 2006, Pages 291-300
Long-Term
Neurocognitive Effects of Olanzapine
or Low-Dose Haloperidol in First-Episode Psychosis
Richard
S.E. Keefe, Larry J. Seidman, Bruce K. Christensen,
Robert M. Hamer, Tonmoy
Sharma, Margriet M. Sitskoorn,
Stephanie L. Rock, Sandra Woolson, Mauricio Tohen, Gary D. Tollefson, Todd M.
Sanger, Jeffrey A. Lieberman and HGDH Research Group
Biological Psychiatry. Volume 59, Issue 2, 15 January 2006, Pages 97-105
The effect of
verbalization strategy on wisconsin card sorting test
performance in schizophrenic patients receiving classical or atypical antipsychotics
Alessandro Rossi, Enrico Daneluzzo, Annarita Tomassini, Francesca Struglia,
Roberto Cavallaro, Enrico Smeraldi and Paolo Stratta
BMC Psychiatry 2006, 6:3; 26 January 2006
Pharmacogenetics for off-patent antipsychotics:
reframing the risk for tardive dyskinesia
and access to essential medicines
Ozdemir V, Aklillu E, Mee S, Bertilsson L, Albers LJ, Graham JE,
Caligiuri M, Lohr JB, Reist C
Expert Opin
Pharmacother.
2006 Feb;7(2):119-33
Atypical Antipsychotic Medication and Substance
Use-Related Outcomes in the Treatment of Schizophrenia
Ismene L. Petrakis, Douglas Leslie,
John W. Finney, Robert Rosenheck
American
Journal on Addictions; Volume 15, Number 1 / 2006: 44 - 49
Prevalence of the Metabolic Syndrome in Veterans
with Schizophrenia
MEYER, JONATHAN; LOH, CATHERINE;
LECKBAND, SUSAN G.; BOYD, JENNIFER A.; WIRSHING, WILLIAM C.; PIERRE, JOSEPH M.;
WIRSHING, DONNA
Journal of Psychiatric Practice. 12(1):5-10, January 2006
Schizophrenia, neuroleptic
medication and mortality
MATTI JOUKAMAA, MARKKU
HELIÖVAARA, PAUL KNEKT, ARPO AROMAA, RAIMO RAITASALO, VILLE LEHTINEN
The British Journal of Psychiatry (2006) 188:
122-127
Off-label prescribing by psychiatrists
Richard Hodgson, Ravindra Belgamwar